BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

429 related articles for article (PubMed ID: 26483565)

  • 1. Prognostic value of different biomarkers for cardiovascular death in unselected older patients in the emergency department.
    Bahrmann P; Christ M; Hofner B; Bahrmann A; Achenbach S; Sieber CC; Bertsch T
    Eur Heart J Acute Cardiovasc Care; 2016 Dec; 5(8):568-578. PubMed ID: 26483565
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multiple biomarker strategy for improved diagnosis of acute heart failure in older patients presenting to the emergency department.
    Bahrmann P; Bahrmann A; Hofner B; Christ M; Achenbach S; Sieber CC; Bertsch T
    Eur Heart J Acute Cardiovasc Care; 2015 Apr; 4(2):137-47. PubMed ID: 25002708
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cardiovascular biomarkers predict post-discharge re-hospitalization risk and mortality among Swedish heart failure patients.
    Molvin J; Jujic A; Bachus E; Gallo W; Tasevska-Dinevska G; Holm H; Melander O; Fedorowski A; Magnusson M
    ESC Heart Fail; 2019 Oct; 6(5):992-999. PubMed ID: 31339668
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic potential of midregional pro-adrenomedullin following decompensation for systolic heart failure: comparison with cardiac natriuretic peptides.
    Morbach C; Marx A; Kaspar M; Güder G; Brenner S; Feldmann C; Störk S; Vollert JO; Ertl G; Angermann CE;
    Eur J Heart Fail; 2017 Sep; 19(9):1166-1175. PubMed ID: 28516504
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cardiovascular biomarkers in patients with cancer and their association with all-cause mortality.
    Pavo N; Raderer M; Hülsmann M; Neuhold S; Adlbrecht C; Strunk G; Goliasch G; Gisslinger H; Steger GG; Hejna M; Köstler W; Zöchbauer-Müller S; Marosi C; Kornek G; Auerbach L; Schneider S; Parschalk B; Scheithauer W; Pirker R; Drach J; Zielinski C; Pacher R
    Heart; 2015 Dec; 101(23):1874-80. PubMed ID: 26416836
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mid-regional pro-atrial natriuretic peptide and pro-adrenomedullin testing for the diagnostic and prognostic evaluation of patients with acute dyspnoea.
    Shah RV; Truong QA; Gaggin HK; Pfannkuche J; Hartmann O; Januzzi JL
    Eur Heart J; 2012 Sep; 33(17):2197-205. PubMed ID: 22645194
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The incremental prognostic and clinical value of multiple novel biomarkers in heart failure.
    Jackson CE; Haig C; Welsh P; Dalzell JR; Tsorlalis IK; McConnachie A; Preiss D; Anker SD; Sattar N; Petrie MC; Gardner RS; McMurray JJ
    Eur J Heart Fail; 2016 Dec; 18(12):1491-1498. PubMed ID: 27114189
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mid-regional pro-adrenomedullin in patients with acute dyspnea: Data from the Akershus Cardiac Examination (ACE) 2 Study.
    Pervez MO; Lyngbakken MN; Myhre PL; Brynildsen J; Langsjøen EC; Høiseth AD; Christensen G; Omland T; Røsjø H
    Clin Biochem; 2017 May; 50(7-8):394-400. PubMed ID: 28065681
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of mid-regional pro-atrial natriuretic peptide, procalcitonin, and mid-regional pro-adrenomedullin for the diagnosis and risk stratification of dyspneic ED patients.
    Cinar O; Cevik E; Acar A; Kaya C; Ardic S; Comert B; Yokusoglu M; Bilgi C; Meisner M; Madsen T
    Am J Emerg Med; 2012 Nov; 30(9):1915-20. PubMed ID: 22742951
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic value of midregional pro-adrenomedullin in patients with acute myocardial infarction: the LAMP (Leicester Acute Myocardial Infarction Peptide) study.
    Khan SQ; O'Brien RJ; Struck J; Quinn P; Morgenthaler N; Squire I; Davies J; Bergmann A; Ng LL
    J Am Coll Cardiol; 2007 Apr; 49(14):1525-32. PubMed ID: 17418290
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative evaluation of B-type natriuretic peptide, mid-regional pro-A-type natriuretic peptide, mid-regional pro-adrenomedullin, and Copeptin to predict 1-year mortality in patients with acute destabilized heart failure.
    Gegenhuber A; Struck J; Dieplinger B; Poelz W; Pacher R; Morgenthaler NG; Bergmann A; Haltmayer M; Mueller T
    J Card Fail; 2007 Feb; 13(1):42-9. PubMed ID: 17339002
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pro-A-type natriuretic peptide, proadrenomedullin, and N-terminal pro-B-type natriuretic peptide used in a multimarker strategy in primary health care in risk assessment of patients with symptoms of heart failure.
    Alehagen U; Dahlström U; Rehfeld JF; Goetze JP
    J Card Fail; 2013 Jan; 19(1):31-9. PubMed ID: 23273592
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Associations of cardiac stress biomarkers with incident type 2 diabetes and changes in glucose metabolism: KORA F4/FF4 study.
    Sujana C; Seissler J; Jordan J; Rathmann W; Koenig W; Roden M; Mansmann U; Herder C; Peters A; Thorand B; Then C
    Cardiovasc Diabetol; 2020 Oct; 19(1):178. PubMed ID: 33066780
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of pleural N-terminal pro-B-type natriuretic peptide, midregion pro-atrial natriuretic peptide and mid-region pro-adrenomedullin for the diagnosis of pleural effusions associated with cardiac failure.
    Porcel JM; Bielsa S; Morales-Rull JL; Civit C; Cao G; Light RW; Esquerda A
    Respirology; 2013 Apr; 18(3):540-5. PubMed ID: 23278975
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adaptive cardiovascular hormones in a spectrum of heart failure phenotypes.
    Zabarovskaja S; Hage C; Linde C; Daubert JC; Donal E; Gabrielsen A; Mellbin L; Lund LH
    Int J Cardiol; 2015; 189():6-11. PubMed ID: 25885866
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Thirty and ninety days mortality predictive value of admission and in-hospital procalcitonin and mid-regional pro-adrenomedullin testing in patients with dyspnea. Results from the VERyfing DYspnea trial.
    Travaglino F; Russo V; De Berardinis B; Numeroso F; Catania P; Cervellin G; Nigra SG; Geraci F; Bressan MA; Guerrini S; Cavazza M; Folli C; Monzani V; Battista S; Mengozzi G; Noto P; Carpinteri G; Semplicini A; Stella F; Ingrassia S; Moscatelli P; Giuntini P; Salerno G; Cardelli P; Di Somma S
    Am J Emerg Med; 2014 Apr; 32(4):334-41. PubMed ID: 24559907
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mid-regional pro-adrenomedullin outperforms N-terminal pro-B-type natriuretic peptide for the diagnosis of acute heart failure in the presence of atrial fibrillation.
    Kuan WS; Ibrahim I; Chan SP; Li Z; Liew OW; Frampton C; Troughton R; Pemberton CJ; Chong JPC; Tan LL; Lin W; Ooi SBS; Richards AM
    Eur J Heart Fail; 2020 Apr; 22(4):692-700. PubMed ID: 31808279
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Additional diagnostic and prognostic value of copeptin ultra-sensitive for diagnosis of non-ST-elevation myocardial infarction in older patients presenting to the emergency department.
    Bahrmann P; Bahrmann A; Breithardt OA; Daniel WG; Christ M; Sieber CC; Bertsch T
    Clin Chem Lab Med; 2013 Jun; 51(6):1307-19. PubMed ID: 23314553
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cardiovascular Mortality in Chest Pain Patients: Comparison of Natriuretic Peptides With Novel Biomarkers of Cardiovascular Stress.
    Sinning C; Ojeda F; Zeller T; Zengin E; Rupprecht HJ; Lackner KJ; Bickel C; Blankenberg S; Schnabel RB; Westermann D
    Can J Cardiol; 2016 Dec; 32(12):1470-1477. PubMed ID: 27568502
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Midregional proadrenomedullin and growth differentiation factor-15 are not influenced by obesity in heart failure patients.
    Sinning C; Ojeda F; Wild PS; Schnabel RB; Schwarzl M; Ohdah S; Lackner KJ; Pfeiffer N; Michal M; Blettner M; Munzel T; Kempf T; Wollert KC; Kuulasmaa K; Blankenberg S; Salomaa V; Westermann D; Zeller T
    Clin Res Cardiol; 2017 Jun; 106(6):401-410. PubMed ID: 28004184
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.